Only time will tell if a larger Phase III study will confirm data on a few dozen patients, but the two-drug combination appears to produce a higher complete response rate than than an existing doublet combination, without the associated toxicity.
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company presented end-of-Phase I data from the trial, on KTE-X19, at the ASCO meeting in Chicago Saturday.
The company plans to present early data in a poster on Saturday showing no more than 1 percent of tests generated false-positive results across 12 solid tumor and blood cancers.
In a position statement, ASCO said PBM practices can result in medication dispensing errors, harm physicians' ability to treat patients and drive up costs.
The legislation, which has drawn criticism from researchers, patient advocates and industry, would enable patients to request experimental drugs while bypassing the FDA.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
Are portals delivering on their promise to engage patients? Or are these results too often a source of confusion and alarm for patients and the cause of more work for doctors because information is provided with little to no guidance?
“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”
The market leader in cancer panel gene testing flooded the zone at the annual meeting of the American Society of Clinical Oncology in Chicago.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The American Society of Clinical Oncology‘s effort to use big data and EHRs to earlier detect cancer just got a $1 million boost from pharma giant Bayer Healthcare. The Society, better known as ASCO, recently launched the effort dubbed CancerLinQ with Germany-based SAP, creating what’s described as an IT platform “designed to unlock vast quantities […]
The American Society of Clinical Oncology is teaming up with SAP on an big data initiative that will use EHRs to examine previously inaccessible information that may lead to early identification on potential cancer patients. As part of the effort, eight oncology centers around the country will use CanderLinQ, a health IT platform that will […]
So far this year, we have covered wearable technology, big data and funding in our monthly Google hangouts. Next month we will be broadcasting live from CONVERGE in Philadelphia. You can join the fun even if you can’t be there live and in person. You don’t have to travel at all to be part of […]
Cancer doctors and patients need a better way to weigh the potential benefits of new targeted cancer treatments against their costs, especially those that carry a price tag north of tens of thousands of dollars per month. That’s why the American Society of Clinical Oncology has put together a task force to develop a scoring […]